News Search Results
Mar 26, 2025, 16:05 ET Congruence Therapeutics Announces Participation in the 24th Annual Needham Virtual Healthcare Conference
March 26, 2025 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's
More news about: Congruence Therapeutics
Mar 26, 2025, 16:00 ET SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) and certain of its officers.
More news about: Bronstein, Gewirtz & Grossman, LLC
Mar 26, 2025, 14:40 ET ICON Public Limited Company Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds ICON Public Limited Company Investors of Deadline in Securities Fraud Class Action Lawsuit
insufficient to shield the company from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 26, 2025, 12:00 ET AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States
market. The company will continue to provide updates as the trial progresses. About AnHorn MedicinesAnHorn is a clinical-stage biotechnology company dedicated to revolutionizing drug discovery through AI-powered innovation. By integrating artificial intelligence with cutting-edge molecular
More news about: AnHorn Medicines
Mar 26, 2025, 10:01 ET CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
biomanufacturing innovations. With increasing clinical success and expanding treatment indications, the market presents significant opportunities for biotechnology companies, healthcare providers, and investors to revolutionize cancer care. Industry experts predict a surge in the development of next-generation
More news about: Astute Analytica
Mar 26, 2025, 10:00 ET JULABO USA EXPANDS NATURAL REFRIGERANT OFFERINGS WITH NEW PRODUCTS
chillers, water baths, immersion coolers, and complementary accessories. JULABO customers span multiple industries including Aerospace, Automotive, Biotechnology, Cannabis, Chemical Manufacturing, Academia, Food & Beverage, Pharmaceutical, Semiconductor and more. Contact Tricia
More news about: Julabo USA
Mar 26, 2025, 08:15 ET BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
March 26, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative
More news about: BrainStorm Cell Therapeutics Inc.
Mar 26, 2025, 08:00 ET Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
March 26, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
Mar 26, 2025, 07:16 ET Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical
More news about: OSR Holdings Inc.
Mar 26, 2025, 07:05 ET Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended
More news about: Leap Therapeutics, Inc.
Mar 26, 2025, 07:00 ET Rice Biotech Launch Pad and RBL LLC to celebrate official launch and lab opening
field of biotechnology as a whole," Rice President Reginald DesRoches said. "Langer has been an incredible leader in translational medicine, pioneering breakthroughs that have transformed drug delivery, tissue engineering and biotechnology and improved
More news about: Rice University
Mar 26, 2025, 07:00 ET Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
our confidence in our innovative approach to treat fibrotic diseases." About Tribune TherapeuticsTribune Therapeutics is a biotechnology company advancing novel medicines to treat fibrosis, regardless of the cause, tissue or diagnosis. The company was founded on groundbreaking structural
More news about: Novo Holdings
Mar 26, 2025, 07:00 ET Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study
More news about: Leap Therapeutics, Inc.
Mar 26, 2025, 06:29 ET ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024
Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, production, commercialization, and international collaboration of innovative biotechnology and small-molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Mar 26, 2025, 06:21 ET Innovent Announces 2024 Annual Results and Business Updates
practices Innovent has been graded 'AAA' rating in MSCI ESG rankings, positioning us at the forefront of the biotechnology industry.We recently launched our ESG website to further strengthen commitment to sustainability, corporate responsibility and ethical
More news about: Innovent Biologics
Mar 26, 2025, 06:00 ET DATAcc by DiMe Releases Resources to Build the Business Case for Digital Endpoints
helps you navigate their roles across different stages of development.The Digital Endpoints ROI Calculator supports pharmaceutical, biotechnology, and digital health technology stakeholders in making data-informed decisions about using digital endpoints. It also helps articulate the measurable
More news about: Digital Medicine Society (DiMe)
Mar 26, 2025, 02:49 ET GenScript Biotech Earns EcoVadis Bronze Medal for the Second Consecutive Year, Ranking Above 83% of Companies
GenScript, we believe that sustainability is not just a goal, but a fundamental part of our mission to make people and nature healthier through biotechnology. By optimizing operations and collaborating with our value chain, we have taken steps forward in reducing environmental impact, promoting ethical
More news about: GenScript Biotech Corporation
Mar 26, 2025, 02:06 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024, inclusive
More news about: THE ROSEN LAW FIRM, P. A.
Mar 25, 2025, 19:30 ET Adcentrx Therapeutics to Showcase Novel STEAP1 and NaPi2b ADCs with Oral and Poster Presentations at AACR 2025
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present new data at the
More news about: Adcentrx Therapeutics
Mar 25, 2025, 16:35 ET Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 25, 2025, 16:30 ET Rgenta Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Mass., March 25, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
Mar 25, 2025, 16:30 ET Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025
March 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and autoimmune diseases, will present updated clinical and translational
More news about: Marengo Therapeutics
Mar 25, 2025, 16:30 ET Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may
More news about: Elevation Oncology
Mar 25, 2025, 15:37 ET Skincare Supplement Market to Reach USD 5,857.59 million by 2032, growing at a 8.50% CAGR - Credence Research
Acquisitions January 2023 – Healthgevity, a dietary supplement company, partnered with Nuritas, a biotechnology firm, to launch LONGEVITY, an anti-aging precision peptide supplement powered by PeptiStrong, a patented next-generation ingredient derived from
More news about: Credence Research Inc.
Mar 25, 2025, 10:59 ET CS Analytical Extends High Voltage Leak Testing Capabilities with Addition of Nikka Densok HDL-1 HVLD Test System
world's only cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to container testing for the pharmaceutical, biotechnology, and medical device industries, is excited to announce that it has acquired, installed and qualified a Nikka Densok HDL-1 High Voltage Leak Detection
More news about: CS Analytical